- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2007. No further regulatory approval milestones are pending.
- Why 3/10
- ISENTRESS is an already-approved, marketed drug with no pending regulatory decision or pivotal readout scheduled in the next ~12 months. As a mature product facing generic erosion, it has no hard binary catalyst ahead.
ISENTRESS is a mature, declining asset for Merck with no upcoming binary catalysts. The key dynamic to watch is the pace of generic erosion: Hetero Labs received final FDA approval for generic raltegravir 400mg in December 2024, and Lupin has tentative approval for the 600mg HD version. Continued sales declines are baked into expectations, but any faster-than-expected erosion or a major label expansion for a newer integrase inhibitor from a competitor could modestly pressure Merck's HIV franchise revenue. For Merck investors, ISENTRESS is a negligible factor relative to Keytruda, Gardasil, and Winrevair.
Price Chart
Executive Summary
ISENTRESS (raltegravir) is Merck & Co.'s first-in-class HIV-1 integrase inhibitor, first approved by the FDA in October 2007. It is a mature, approved product with no pending regulatory catalysts. The drug faces growing headwinds: generic competition entered the market in December 2024 (Hetero Labs received final FDA approval for generic raltegravir 400mg), and newer once-daily integrase inhibitors like dolutegravir and bictegravir have eroded its market position. Sales have been declining (roughly $394M in 2024, down from $483M in 2023). Merck has extended the franchise with ISENTRESS HD (once-daily 1200mg), a pediatric oral suspension, and a neonatal indication, but these are niche additions. For Merck, a $346B market cap company with $65B in annual revenue, ISENTRESS is a negligible revenue contributor (less than 1% of sales) and not a stock-moving catalyst in either direction.
How It Works
ISENTRESS is an antiretroviral drug that treats HIV-1 infection by blocking an enzyme called integrase, which the HIV virus needs to insert its genetic material into the DNA of human immune cells. By stopping this integration step, the drug prevents the virus from replicating and reduces the viral load in the body. It is always used in combination with other antiretroviral agents, never as a standalone treatment.
Trial Status
ISENTRESS is a fully approved, commercially marketed drug. The most recent label expansion was FDA approval for use in neonates (newborns from birth to 4 weeks of age weighing at least 2 kg), supported by the IMPAACT P1110 study. A pediatric oral suspension formulation was also approved. No active pivotal clinical trials are ongoing for new indications.
The Two-Sided Case
Upcoming Catalysts
- No upcoming binary catalysts for ISENTRESS specifically. The drug is mature and facing generic erosion. Merck's overall Q3 2026 earnings were reported on October 29, 2026 (today), but ISENTRESS is too small to move the stock.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report